Most patients experience significant weight loss and can lose 5-10% of their body weight over the course of 6 months with weekly injections
Based on these data, an ongoing phase 1/2a, multicenter, open-label, ascending dose, first in-human clinical trial is planned to evaluate the safety of intracisternal PR001A (AAV9-GBA1) administration in patients with moderate to severe PD with at least one GBA pathogenic variant (NCT04127578, Table 2)
"The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials." Obesity Reviews
If possible, keep these items in their original packaging to minimize confusion
Inspect previous sites regularly : Before applying a new patch, examine previous application sites for signs of skin reaction, including persistent redness, swelling, itching, or rash
This bypasses the strict prior authorization requirements of insurance companies, making the medication accessible to patients who might otherwise be denied coverage